255 related articles for article (PubMed ID: 29761382)
1. Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension.
Hoy SM
Drugs; 2018 May; 78(7):773-780. PubMed ID: 29761382
[TBL] [Abstract][Full Text] [Related]
2. Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension.
Kaufman PL
Expert Opin Pharmacother; 2017 Mar; 18(4):433-444. PubMed ID: 28234563
[TBL] [Abstract][Full Text] [Related]
3. Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension.
Fingeret M; Gaddie IB; Bloomenstein M
Clin Exp Optom; 2019 Nov; 102(6):541-550. PubMed ID: 30614563
[TBL] [Abstract][Full Text] [Related]
4. Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings.
Weinreb RN; Liebmann JM; Martin KR; Kaufman PL; Vittitow JL
J Glaucoma; 2018 Jan; 27(1):7-15. PubMed ID: 29194198
[TBL] [Abstract][Full Text] [Related]
5. Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study.
Weinreb RN; Scassellati Sforzolini B; Vittitow J; Liebmann J
Ophthalmology; 2016 May; 123(5):965-73. PubMed ID: 26875002
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Latanoprostene Bunod 0.024% Compared With Timolol 0.5% in Lowering Intraocular Pressure Over 24 Hours.
Liu JHK; Slight JR; Vittitow JL; Scassellati Sforzolini B; Weinreb RN
Am J Ophthalmol; 2016 Sep; 169():249-257. PubMed ID: 27457257
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 h in Healthy Japanese Subjects.
Araie M; Sforzolini BS; Vittitow J; Weinreb RN
Adv Ther; 2015 Nov; 32(11):1128-39. PubMed ID: 26563323
[TBL] [Abstract][Full Text] [Related]
8. Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma.
Wang Y; Liao Y; Nie X
Clinics (Sao Paulo); 2020; 75():e1874. PubMed ID: 33263632
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study.
Medeiros FA; Martin KR; Peace J; Scassellati Sforzolini B; Vittitow JL; Weinreb RN
Am J Ophthalmol; 2016 Aug; 168():250-259. PubMed ID: 27210275
[TBL] [Abstract][Full Text] [Related]
10. Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study.
Kawase K; Vittitow JL; Weinreb RN; Araie M;
Adv Ther; 2016 Sep; 33(9):1612-27. PubMed ID: 27457469
[TBL] [Abstract][Full Text] [Related]
11. Latanoprost : an update of its use in glaucoma and ocular hypertension.
Perry CM; McGavin JK; Culy CR; Ibbotson T
Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
[TBL] [Abstract][Full Text] [Related]
12. New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost.
Mehran NA; Sinha S; Razeghinejad R
Eye (Lond); 2020 Jan; 34(1):72-88. PubMed ID: 31695162
[TBL] [Abstract][Full Text] [Related]
13. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
Easthope SE; Perry CM
Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
[TBL] [Abstract][Full Text] [Related]
14. The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies.
Cavet ME; DeCory HH
J Ocul Pharmacol Ther; 2018; 34(1-2):52-60. PubMed ID: 28783422
[TBL] [Abstract][Full Text] [Related]
15. Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma.
Mehta AA; Kanu LN; Sood-Mendiratta S; Quinones R; Hawkins A; Lehrer RA; Malhotra K; Papas R; Hillman D; Wilensky JT; Aref AA; Vajaranant TS; Edward DP
Eur J Ophthalmol; 2022 Jan; 32(1):322-326. PubMed ID: 33653172
[TBL] [Abstract][Full Text] [Related]
16. Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2.
Asrani S; Bacharach J; Holland E; McKee H; Sheng H; Lewis RA; Kopczynski CC; Heah T
Adv Ther; 2020 Apr; 37(4):1620-1631. PubMed ID: 32166538
[TBL] [Abstract][Full Text] [Related]
17. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study.
Weinreb RN; Ong T; Scassellati Sforzolini B; Vittitow JL; Singh K; Kaufman PL;
Br J Ophthalmol; 2015 Jun; 99(6):738-45. PubMed ID: 25488946
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of latanoprost and latanoprostene bunod on intraocular pressure and pupil size in ophthalmologically normal Beagle dogs.
Desai SJ; Pumphrey SA; Koethe B
Vet Ophthalmol; 2022 Jul; 25(4):282-290. PubMed ID: 35247289
[TBL] [Abstract][Full Text] [Related]
19. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
20. [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)].
Ge J; Li X; Sun X; He X; Zhang H
Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):95-102. PubMed ID: 25907999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]